A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
A phase 2 trial of Telisotuzumab adizutecan, Fluorouracil, CAPOX in colorectal cancer, run by AbbVie, now recruiting.
Overview
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT06820463 by AbbVie, with 390 participants planned, started 2025-04-24 and due to reach its primary completion in 2028-03. Interventions recorded: Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese
Shares Telisotuzumab adizutecan, Fluorouracil (5-FU), AbbVie (incl. ImmunoGen, Capstan), Bevacizumab.
- TrialBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Colorectal cancer.
- TrialA Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Bevacizumab.
- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
- TrialA Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Bevacizumab, Colorectal cancer.